Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04787471 · ClinicalTrials.gov registry record · Phase 2
Corneal Crosslinking for Treatment of Corneal Neovascularization
A Phase 2 study of Corneal Neovascularization, sponsored by Price Vision Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT04787471 is a Phase 2 study of Corneal Neovascularization that is actively recruiting participants, run by Price Vision Group. The registered enrollment target is 62 participants, roughly in line with the 62-participant average among 3 other Corneal Neovascularization trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT04787471, a Phase 2 study of Corneal Neovascularization, is actively recruiting participants, sponsored by Price Vision Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
Conditions Studied
Interventions
- COMBINATION_PRODUCT 30 minute photoactivation of riboflavin 0.1%
- COMBINATION_PRODUCT 10 minute photoactivation of riboflavin 0.1%
Study Locations (1)
Indiana
- Price Vision Group - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2026-09-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04787471
The ClinicalTrials.gov registry entry for NCT04787471 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 62-participant average among 3 other Corneal Neovascularization trials with a reported enrollment target. The listed sponsor is Price Vision Group, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Corneal Neovascularization appearing as the primary indexed condition, and to 2 interventions - of which 30 minute photoactivation of riboflavin 0.1% is the first listed.
NCT04787471 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT04787471 about?
NCT04787471 is a clinical study titled "Corneal Crosslinking for Treatment of Corneal Neovascularization". The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
What is the current status of trial NCT04787471?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2021-05-03. Estimated completion is 2026-09-15.
What conditions does trial NCT04787471 study?
This clinical trial studies the following conditions: Corneal Neovascularization.
What interventions are being tested in trial NCT04787471?
The interventions under investigation include: 30 minute photoactivation of riboflavin 0.1% (COMBINATION_PRODUCT), 10 minute photoactivation of riboflavin 0.1% (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04787471?
This trial is sponsored by Price Vision Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04787471 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Neovascularization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
COMPLETED · Phase 1
-
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
COMPLETED · NA
-
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.